Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Financing Activities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cash from Financing Activities for 17 consecutive years, with -$8.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 490.48% to -$8.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $64.2 million, a 967.57% increase, with the full-year FY2025 number at $64.2 million, up 967.57% from a year prior.
  • Cash from Financing Activities was -$8.2 million for Q4 2025 at Myriad Genetics, down from $56.2 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $121.9 million in Q4 2023 to a low of -$74.5 million in Q3 2021.
  • A 5-year average of $2.6 million and a median of -$2.3 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: crashed 24350.0% in 2021, then surged 5904.76% in 2023.
  • Myriad Genetics' Cash from Financing Activities stood at -$1.1 million in 2021, then crashed by 90.91% to -$2.1 million in 2022, then soared by 5904.76% to $121.9 million in 2023, then crashed by 98.28% to $2.1 million in 2024, then plummeted by 490.48% to -$8.2 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Cash from Financing Activities are -$8.2 million (Q4 2025), $56.2 million (Q3 2025), and $2.6 million (Q2 2025).